Rasoul-Rockenschaub S, Zielinski C C, Kubista E, Vavra N, Pospischil E, Staffen A, Czerwenka K, Aiginger P, Spona J
Department of Medicine II, University Hospital, Vienna, Austria.
Eur J Cancer Clin Oncol. 1989 Jul;25(7):1067-72. doi: 10.1016/0277-5379(89)90390-8.
The diagnostic value of mucin-like carcinoma-associated antigen (MCA) was compared to that of carcinoembryonic antigen (CEA) and/or CA 15.3 in patients with breast cancer. A total of 368 patients with breast cancer were studied, of whom 253 were free of metastases, whereas 94 had either skeletal or visceral metastases or diffuse metastatic disease. The diagnostic sensitivity of MCA proved to be comparable to that of CA 15.3 and superior to that of CEA in patients with metastatic breast cancer. In contrast, the specificity of MCA was superior to that of CA 15.3. Finally, the diagnostic sensitivity of each of the tested tumour markers, i.e. MCA, CEA and CA 15.3, could be improved by their combined use. We conclude that MCA, either alone or in combination with CA 15.3 and CEA, can improve the monitoring of disease progression in patients with metastatic breast cancer.
在乳腺癌患者中，对黏蛋白样癌相关抗原（MCA）的诊断价值与癌胚抗原（CEA）和/或CA 15.3的诊断价值进行了比较。共研究了368例乳腺癌患者，其中253例无转移，而94例有骨转移或内脏转移或弥漫性转移疾病。在转移性乳腺癌患者中，MCA的诊断敏感性被证明与CA 15.3相当，且优于CEA。相比之下，MCA的特异性优于CA 15.3。最后，通过联合使用所检测的每种肿瘤标志物，即MCA、CEA和CA 15.3，其诊断敏感性均可提高。我们得出结论，MCA单独使用或与CA 15.3和CEA联合使用，均可改善转移性乳腺癌患者疾病进展的监测。
